.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Daiichi Sankyo
Moodys
QuintilesIMS
AstraZeneca
US Department of Justice
Chubb
Citi
Cerilliant
Colorcon

Generated: September 24, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Therapeutic nucleosides
Abstract:The present invention relates to 6-substituted purine carbocyclic nucleosides and their use in medical therapy particularly in the treatment of HIV and HBV infections. Also provided are pharmceutical formulations and processes for the preparation of compounds according to the invention.
Inventor(s): Daluge; Susan M. (Chapel Hill, NC)
Assignee: Burroughs Wellcome Co. (Research Triangle Park, NC)
Application Number:07/697,260
Patent Claims: 1. A method of treatment of a viral infection in a mammal which comprises administering to said mammal an effective antiviral amount of a compound of formula I: ##STR4## wherein R.sup.3 represents hydrogen or C.sub.1-6 alkyl; R.sup.6 represents C.sub.3-8 cycloalkyl, and R.sup.7 represents a hydrogen atom or a branched or straight chain C.sub.l-6 alkyl; or a pharmaceutically acceptable ester or a pharmaceutically acceptable salt thereof.

2. The method according to claim 1 for the treatment of an HIV infections.

3. A method according to claim 1 for the treatment of a hepatitis B infection.

4. A method according to claim 2 wherein the antiviral compound is (-)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-me thanol or racemic or partially resolved mixtures with the (+)-cis enantiomer thereof.

5. A method according to claim 3 wherein the antiviral compound is (-)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-me thanol or racemic or partially resolved mixtures with the (+)-cis enantiomer thereof.

6. A method according to claim 1 comprising administering to said mammal 15 to 60 mg/kg of body weight per day of a compound of formula I or a pharmaceutically acceptable salt or a pharmaceutically acceptable ester thereof.

7. A method according to claim 6 in which the infection is an HIV infection and the mammal is a human.

8. A method according to claim 6 in which the infection is a hepatitis B infection and the mammal is a human.

9. A method of treating an HIV infection in a mammal which comprises administering to said mammal an effective anti-HIV amount of (-)-cis-4-{2-amino-6-(cyclopropylamino)-9H-purin-9-yl}-2-cyclopentene-1-me thanol or racemic or partially resolved mixtures thereof with the (+)-cis-enantiomer or a pharmaceutically acceptable ester or a pharmaceutically acceptable salt thereof.

10. A method of treating an HIV infection in a mammal which comprises administering to said mammal an effective anti-HIV amount of (-)-cis-4-{2-amino-6-(cyclopropylmethylamino)-9H-purin-9-yl{-2-cyclopenten e-1-methanol or racemic or partially resolved mixtures thereof with the (+)-cis-enantiomer or a pharmaceutically acceptable ester or a pharmaceutically acceptable salt thereof.

11. A method according to claim 9 or 10, in which the pharmaceutically acceptable ester is a mono-, di- or triphosphate.

12. A method according to claim 9 or 10, in which the pharmaceutically acceptable salt is hydrochloride.

13. A method according to claim 9 or 10, in which the mammal is a human.

14. A method of treating an HIV infection in a mammal which comprise administering to said mammal an effective anti-HIV amount of (-)-cis-4-{2-amino-6-(cyclopropylamino)-9H-purin-9-yl}-2-cyclopentene-1-me thanol or racemic or partially resolved mixtures thereof with the (+)-cis-enantiomer or a pharmaceutically acceptable ester or a pharmaceutically acceptable salt thereof.

15. A method of treating an HIV infection in a mammal which comprises administering to said mammal an effective anti-HIV amount of (-)-cis-b 4-{2-amino-6-(cyclopropylmethylamino)-9H-purin-9-yl}-2-cyclopentene-1-meth anol or racemic or partially resolved mixtures thereof with the (+)-cis-enantiomer or a pharmaceutically acceptable ester or a pharmaceutically acceptable salt thereof.

16. A method according to claim 14 or 15, in which the pharmaceutically acceptable ester is a mono- , di- or tri-phosphate.

17. A method according to claim 14 or 15, in which the mammal is a human.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
Colorcon
McKesson
Accenture
Fish and Richardson
Merck
Express Scripts
Mallinckrodt
QuintilesIMS
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot